STAGE IV RENAL PELVIS CANCER AJCC V8

This study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…

This study is testing if adding a common, low-cost blood pressure medication called propranolol to standard immunotherapy helps people with advanced bladder cancer. Six participants will receive either immunotherapy alone or immunotherapy plus propranolol. The main goal is to see…

This early-stage trial is testing a combination of two targeted drugs, erdafitinib and enfortumab vedotin, for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The main goals are to find the safest and most effective dose of the drug…

This large, late-stage trial is testing if adding a pill called cabozantinib to an immunotherapy drug (avelumab) is better than the immunotherapy alone for keeping advanced bladder cancer from growing or returning. It is for patients whose cancer did not worsen after their first …

This study is for people with advanced bladder cancer that has spread or come back and cannot be treated with cisplatin. It is testing if adding a chemotherapy drug (eribulin) to an immunotherapy drug (atezolizumab) works better and is safe compared to using the immunotherapy alo…

This study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…